Jun 4, 2026 08:02AM
Jun 4, 2026 08:00AM
May 27, 2026 08:00AM
May 27, 2026 08:00AM
May 14, 2026 08:01AM
May 14, 2026 08:00AM
May 13, 2026 08:04AM MIRA Pharmaceuticals publishes peer-reviewed study on obesity drug candidate
May 13, 2026 08:00AM
Mar 4, 2026 08:00AM
Mar 4, 2026 08:00AM
Feb 3, 2026 07:31AM
Feb 3, 2026 07:30AM
Oct 24, 2025 07:30AM
Oct 24, 2025 07:30AM MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
Sep 16, 2025 07:30AM
Sep 16, 2025 07:30AM
Aug 19, 2025 08:30AM
Aug 19, 2025 08:30AM
Aug 12, 2025 08:32AM
Aug 12, 2025 08:30AM
Jul 30, 2025 07:30AM MIRA Pharmaceuticals topical Ketamir-2 matches morphine in preclinical study
Jul 30, 2025 07:30AM
Jul 29, 2025 07:31AM
Jul 29, 2025 07:30AM
May 6, 2025 08:02AM
May 6, 2025 08:00AM
Apr 23, 2025 08:04AM
Apr 23, 2025 08:00AM MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
Apr 16, 2025 08:03AM
Apr 16, 2025 08:00AM
Apr 1, 2025 08:00AM
Mar 24, 2025 07:33AM
Mar 24, 2025 07:30AM
Mar 13, 2025 08:00AM
Mar 4, 2025 08:02AM Mira Pharma (MIRA) Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
Mar 4, 2025 08:00AM
Dec 19, 2024 09:02AM
Dec 19, 2024 09:00AM
Dec 10, 2024 08:34AM
Dec 10, 2024 08:30AM
Oct 28, 2024 07:41AM
Oct 28, 2024 07:30AM MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
Oct 21, 2024 07:47AM
Oct 21, 2024 07:30AM
Sep 27, 2024 07:32AM
Sep 27, 2024 07:30AM
Sep 18, 2024 07:05AM
Sep 18, 2024 07:00AM
Sep 11, 2024 07:33AM Mira Pharma (MIRA) Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
Sep 11, 2024 07:30AM

323,325 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All